Benzinga | Aug 10, 2021 08:02AM EDT

F-star Therapeutics Reports Granted Composition Of Matter Patent For Its Novel Second-Gen STING Agonist, SB 11285

F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent (U.S. Patent No. 11,033,569) protecting the composition of matter of F-star's SB 11285, a second generation STING agonist. The patent protection is expected to continue to July 2037, not including any potential patent term extensions.

Neil Brewis, Ph.D., Chief Scientific Officer of F-star, said: "We are encouraged by the latest interim results from the dose-escalation study of SB 11285. Securing patent protection in the U.S. at this critical time in the development of our second-generation STING agonist will ensure advancement of the compound with exclusivity in our approach."